Figure S17 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

<p>Sensitivity to ibrutinib was evaluated by MTT assay (72h). Karpas1718 parental (top) or resistant (bottom) were exposed to 100nM decitabine (A), 5µM tazemetostat (B), or DMSO (control, black) given concomitantly (continuous lines) or 72 hours before ibrutinib (pre DMSO in dashed black or pre decitabine/tazemetostat in dashed red). Error bars correspond to standard deviation of the mean. Data derived from two independent experiments. Statistically significant differences were evaluated by moderated t-test comparing each treatment to control (DMSO).</p>